Methods for treating conditions associated with MASP-2 dependent complement activation

Patent metadata

Field	Value
Publication number	US-9644035-B2
Application number	US-201313830831-A
Country	US
Kind code	B2
Filing date	Mar 14, 2013
Priority date	Apr 8, 2011
Publication date	May 9, 2017
Grant date	May 9, 2017

Abstract

In one aspect, the invention provides methods of inhibiting the effects of MASP-2-dependent complement activation in a living subject. The methods comprise the step of administering, to a subject in need thereof, an amount of a MASP-2 inhibitory agent effective to inhibit MASP-2-dependent complement activation. In some embodiments, the MASP-2 inhibitory agent inhibits cellular injury associated with MASP-2-mediated alternative complement pathway activation, while leaving the classical (Clq-dependent) pathway component of the immune system intact. In another aspect, the invention provides compositions for inhibiting the effects of lectin-dependent complement activation, comprising a therapeutically effective amount of a MASP-2 inhibitory agent and a pharmaceutically acceptable carrier.

First claim

The embodiment of the invention in which an exclusive property or privilege is claimed are defined as follows:

1. A method of inhibiting MASP-2-dependent complement activation in a subject suffering from or at risk for developing atypical hemolytic uremic syndrome (aHUS), comprising administering to the subject a composition comprising an amount of a MASP-2 inhibitory agent effective to inhibit MASP-2 dependent complement activation, wherein said MASP-2 inhibitory agent is an anti-MASP-2 monoclonal antibody or fragment thereof that specifically binds to a portion of SEQ ID NO:6.

2. The method of claim 1 , wherein prior to administration of the composition the subject is determined to exhibit one or more symptoms selected from the group consisting of (i) anemia, (ii) thrombocytopenia (iii) renal insufficiency and (iv) rising creatinine, and the composition is administered in an effective amount and for a sufficient time period to improve said one or more symptoms.

3. The method of claim 1 , wherein the subject is suffering from or at risk for developing non-Factor H-dependent aHUS.

4. The method of claim 1 , wherein the subject is suffering from aHUS associated with factor I, factor B, or membrane cofactor CD46.

5. A method of inhibiting MASP-2-dependent complement activation in a subject suffering from, or at risk for developing, atypical hemolytic uremic syndrome (aHUS) secondary to an infection, comprising administering to the subject a composition comprising an amount of a MASP-2 inhibitory agent effective to inhibit MASP-2 complement activation wherein said MASP-2 inhibitory agent is an anti-MASP-2 monoclonal antibody, or fragment thereof that specifically binds to a portion of SEQ ID NO:6.

6. The method of claim 5 , wherein the subject is suffering from, or at risk for developing non-enteric aHUS associated with an S. pneumonia infection.

7. A method of treating a subject suffering from atypical hemolytic uremic syndrome (aHUS) comprising administering to the subject a composition comprising an amount of a MASP-2 inhibitory agent effective to inhibit MASP-2 dependent complement activation, wherein the administration of the MASP-2 inhibitory agent is administered via an intravenous catheter or other catheter delivery method wherein said MASP-2 inhibitory agent is an anti-MASP-2 monoclonal antibody, or fragment thereof that specifically binds to a portion of SEQ ID NO:6.

8. The method of claim 7 , further comprising treating the patient with plasmapheresis.

9. The method of claim 7 , wherein the composition comprising the MASP-2 inhibitory agent is administered in the absence of plasmapheresis.

10. The method of claim 9 , wherein the composition comprising the MASP-2 inhibitory agent is administered via a catheter for a first time period, further comprising administering the composition comprising the MASP-2 inhibitory agent for a second time period, Wherein the composition is administered subcutaneously during the second time period.

11. The method of claim 1 , 5 or 7 , wherein the anti-MASP-2 antibody selectively inhibits MASP-2-dependent complement activation without substantially inhibiting the Clq-dependent complement pathway.

12. The method of claim 1 , 5 or 7 , wherein the MASP-2 inhibitory agent specifically binds to a polypeptide comprising SEQ ID NO:6 with an affinity of at least 10 times greater than it binds to a different polypeptide in the complement system.

13. The method of claim 1 , 5 or 7 , wherein the monoclonal antibody or antigen-binding fragment thereof is human or humanized.

14. The method of claim 1 , 5 or 7 , wherein the monoclonal antibody or antigen-binding fragment thereof is a recombinant antibody.

15. The method of claim 1 or 5 , wherein the composition is administered subcutaneously.

Assignees

• Omeros Corp
• Univ Leicester

Inventors

• Demopulos Gregory A
• Dudler Thomas
• Schwaeble Hans-Wilhelm

Classifications

• A61K39/3955

  against proteinaceous materials, e.g. enzymes, hormones, lymphokines · CPC title

• C07K2317/92

  Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value · CPC title

• C07K2317/21

  from primates, e.g. man · CPC title

• C07K16/40 Primary

  against enzymes · CPC title

• C07K2317/54

  F(ab')2 · CPC title